High Tower Advisors, LLC Summit Therapeutics Inc. Transaction History
High Tower Advisors, LLC
- $64.2 Billion
- Q2 2024
A detailed history of High Tower Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 39,050 shares of SMMT stock, worth $784,905. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,050
Previous 64,050
39.03%
Holding current value
$784,905
Previous $265,000
14.72%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$467 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$177 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$82.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$59.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.04B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...